FDA Speeds Up Process for Two More Anti-Amyloids
Today, the experimental Eli Lilly drug donanemab received the FDA’s “breakthrough therapy designation” based on its potential to treat Alzheimer’s disease. The FDA granted…
Today, the experimental Eli Lilly drug donanemab received the FDA’s “breakthrough therapy designation” based on its potential to treat Alzheimer’s disease. The FDA granted…
Instead of developing a new drug from the ground up — a time-consuming and costly process — experts say that repurposing medications could accelerate…
UPDATE: 3 March 2024, 8:33 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Nearly every Alzheimer’s clinical trial has been deemed a failure, yet some participants have positively responded to experimental treatment. Now, scientists are developing predictive…
Biogen’s aducanumab — a human antibody-based drug that targets beta-amyloid plaques, which are found in the brains of people with Alzheimer’s — has gone…
Scientists are diversifying their approaches to finding an effective treatment for Alzheimer’s as clinical trials targeting beta-amyloid plaques, one of the hallmarks of the…
In 2013, Amylyx Pharmaceuticals co-founders Justin Klee and Josh Cohen, undergraduate students at Brown University at the time, hypothesized that targeting two dysfunctional pathways…
Developing a new drug start to finish can take years — even decades — and cost billions. But, there’s a shortcut: repurposing old drugs…
This weekend, Eli Lilly and Company presented detailed results of its phase 2 TRAILBLAZER-ALZ trial, showing that its investigational drug donanemab — monoclonal antibody…
Wall Street traders seem to have gained a new favorite potential Alzheimer’s treatment as shares of Cassava Science, a small and virtually unknown company,…
Biogen’s Alzheimer’s drug aducanumab encounters another bump in the road as the FDA delays its approval decision. The Federal Drug Administration has given itself…
The initial results from Eli Lilly and Co’s Phase 2 clinical trial for experimental Alzheimer’s drug donanemab provide much needed hope for the Alzheimer’s…
In a surprising turn of events, the Advisory Committee of experts on Biogen’s experimental Alzheimer’s drug aducanumab recommended against FDA approval of the drug…
This article was produced by Being Patient in partnership with Charter Research. More information on Alzheimer’s clinical trials can be found on the Charter…
Sponsored: This article was produced by Being Patient in partnership with Charter Research. More information on Alzheimer’s clinical trials can be found on the…